


EXPERT INSIGHTS INTO A DEADLY DISEASE:

TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM)



KEY SPEAKERS

Jamieson Bourque MD, MHS

Noel Dasgupta, MD

Nitasha Sarswat, MD

DATE: SATURDAY MARCH 16, 2019

TIME: 6:30PM to 8:30PM (DOORS OPEN AT 6:00PM)

LOCATION: SHERATON NEW ORLEANS HOTEL
500 CANAL ST, NEW ORLEANS, LA 70130
GRAND BALLROOM AB, 5TH FLOOR

DINNER WILL BE SERVED

ATTR-CM is a **life-threatening**, **underrecognized**, and **underdiagnosed** condition, although awareness of the disease continues to increase.¹⁻³

Please join us for an informative symposium, during which ATTR-CM experts will:

- ▶ Provide a comprehensive overview of cardiac amyloidosis
- ▶ Describe the mechanism of disease for ATTR-CM
- ▶ Review clinical manifestations and other considerations that can help raise suspicion of ATTR-CM
- ▶ Discuss diagnostic modalities that can help confirm suspicion of ATTR-CM

This event, intended for healthcare professionals, is not part of ACC.19, as planned by its Program Committee, and does not qualify for continuing medical education (CME), continuing nursing education (CNE), or continuing education (CE) credit.

References: 1. Maurer MS, Elliott P, Comenzo R, Semigran M, Rapezzi C. Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis. *Circulation*. 2017;135(14):1357-1377. 2. Sipe JD, Benson MD, Buxbaum JN, et al. Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines. *Amyloid*. 2016;23(4):209-213. 3. Connors LH, Sam F, Skinner M, et al. Heart failure resulting from age-related cardiac amyloid disease associated with wild-type transthyretin: a prospective, observational cohort study. *Circulation*. 2016;133(3):282-290.